Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Decreases By 50.3%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant decline in short interest in April. As of April 15th, there was short interest totaling 3,285 shares, a decline of 50.3% from the March 31st total of 6,607 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 5,026 shares, the short-interest ratio is currently 0.7 days.

Global X Genomics & Biotechnology ETF Stock Down 0.9%

NASDAQ:GNOM traded down $0.42 during mid-day trading on Monday, hitting $45.55. 5,725 shares of the stock traded hands, compared to its average volume of 8,698. The business’s 50-day moving average price is $45.21 and its 200 day moving average price is $45.54. The company has a market cap of $51.02 million, a PE ratio of -19.47 and a beta of 1.23. Global X Genomics & Biotechnology ETF has a 12-month low of $29.44 and a 12-month high of $51.42.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently bought and sold shares of the company. IFP Advisors Inc grew its stake in Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Wealth Management Partners LLC purchased a new position in Global X Genomics & Biotechnology ETF during the first quarter valued at approximately $244,000. Creative Financial Designs Inc. ADV grew its stake in Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $575,000. Finally, Smartleaf Asset Management LLC grew its stake in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares in the last quarter. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.